• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu
VIEW ALL RESEARCH-GROUP

Molecular signaling
Viñals’s lab

DESCRIPTION

Our research is focused on the study of the implication of intracellular signaling cascades driving to pathological situations in cancer and vascular diseases.

The molecular signaling cascades that take place inside the cells are essential to respond to changes in their environment or to alter their homeostasis, for example, at the level of cell proliferation, movement, growth or metabolism. Understanding how these mechanisms of signal transduction work can explain how biological processes are controlled in a normal physiological context, but also, the alterations that take place in many pathologies. Our group investigates this in two pathological contexts: The first is ovarian epithelial cancer, where we study the pathways involved in metastasis and the mechanisms of resistance to therapies. A second context is a rare vascular disease, HHTs, in which, in collaboration with the group led by Toni Riera (Hospital de Bellvitge), we study which signaling pathways are altered in patients with mutations that cause this disease, and how treat them with new drugs.

Group members

Francesc Viñals

Group leaders

Group Leader

Agnès Figueras

Researchers

Núria Gendrau Sanclemente

PhD student

Ferran Medina Jover

PhD student

José Luís Rocamora

PhD student

Tianyu Dai

PhD student

Publications

Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis

18 de September de 2013/in Viñals's lab/by miguel

J Exp Med. 2013 Sep 23;210(10):1937-45. doi: 10.1084/jem.20121571. Epub 2013 Sep 16. ABSTRACT Understanding the direct, tumor cell-intrinsic effects of PI 3-kinase (PI3K) has been a key focus of research to date. Here, we report that cancer cell-extrinsic PI3K activity, mediated by the p110α isoform of PI3K, contributes in an unexpected way to tumor angiogenesis. […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-09-18 10:00:002013-09-18 10:00:00Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis

Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors

14 de August de 2013/in Viñals's lab/by miguel

BMC Cancer. 2013 Aug 10;13:382. doi: 10.1186/1471-2407-13-382. ABSTRACT BACKGROUND: Cisplatin (CDDP) resistance in testicular germ cell tumors (GCTs) is still a clinical challenge, and one associated with poor prognosis. The purpose of this work was to test pazopanib, an anti-tumoral and anti-angiogenic multikinase inhibitor, and its combination with lapatinib (an anti-ErbB inhibitor) in mouse orthotopic […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-08-14 10:00:002013-08-14 10:00:00Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors

CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer

19 de June de 2013/in Viñals's lab/by miguel

EMBO Mol Med. 2013 Jul;5(7):1067-86. doi: 10.1002/emmm.201202341. Epub 2013 Jun 14. ABSTRACT SCF (Skp1/Cul1/F-box) ubiquitin ligases act as master regulators of cellular homeostasis by targeting key proteins for ubiquitylation. Here, we identified a hitherto uncharacterized F-box protein, FBXO28 that controls MYC-dependent transcription by non-proteolytic ubiquitylation. SCF(FBXO28) activity and stability are regulated during the cell cycle […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-06-19 10:00:002013-06-19 10:00:00CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer

Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells

8 de May de 2013/in Viñals's lab/by miguel

Int J Cancer. 2013 Nov 15;133(10):2464-72. doi: 10.1002/ijc.28259. Epub 2013 Jun 4. ABSTRACT In this article, the effectiveness of a multi-targeted chemo-switch (C-S) schedule that combines metronomic chemotherapy (MET) after treatment with the maximum tolerated dose (MTD) is reported. This schedule was tested with gemcitabine in two distinct human pancreatic adenocarcinoma orthotopic models and with […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-05-08 10:00:002013-05-08 10:00:00Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells

The impact of KRAS mutations on VEGF-A production and tumour vascular network

20 de March de 2013/in Viñals's lab/by miguel

BMC Cancer. 2013 Mar 18;13:125. doi: 10.1186/1471-2407-13-125. ABSTRACT BACKGROUND: The malignant potential of tumour cells may be influenced by the molecular nature of KRAS mutations being codon 13 mutations less aggressive than codon 12 ones. Their metabolic profile is also different, with an increased anaerobic glycolytic metabolism in cells harbouring codon 12 KRAS mutations compared […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2013-03-20 10:00:002013-03-20 10:00:00The impact of KRAS mutations on VEGF-A production and tumour vascular network
Page 12 of 23«‹1011121314›»

Research Projects

– Ref: PID2020-117815RB-I00 Title: El perfil metabólico como una oportunidad terapéutica en el cáncer epitelial de ovario. implicaciones en metástasis y resistencia a los tratamientos. DGICYT, MINECO. 2021-2024. 217.800 euros. Principal Investigator: Francesc Viñals Canals, IDIBELL.

– Ref: SAF2017-85869-R Title: Mecanismos de señalización y control metabólico implicados en la diseminación y quimioresistencia en cáncer epitelial de ovario. DGICYT, MINECO. 2018-2020. 181.500 euros. Principal Investigator: Francesc Viñals Canals, IDIBELL.

Collaborations

Peter B. Vermeulen, University of Antwerp and GZA Hospitals, Belgium
Artur Mezheyeuski, VHIO, Barcelona
Pnina Brodt, Mc Gill University, Montreal, Canada
and Liver Metastases Research Network members

Viñals's lab
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Casanovas’ LabCasanovas's Lab
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}